BACKGROUND: The purpose of this study was to determine the frequency of a polymorphism of the candidate metabolic enzyme N-acetyltransferase-2 (NAT2) in Japanese prostate cancer patients and Japanese non-cancer controls, in order to determine if an association exists between NAT2 genotype and the occurrence, clinical stage and grade of prostate cancer. METHODS: In the present case-control study, 111 patients with prostate cancer and 152 controls were genotyped for the NAT2 polymorphism using the polymerase chain reaction-based restriction fragment length polymorphism method. The NAT2 genotypes (slow or rapid acetylator genotype) were determined by the combination of three known NAT2 mutant alleles (M1, M2, M3) and the wild-type allele. RESULTS: The NAT2 slow acetylator genotype was statistically higher among prostate cancer patients (17.1%) compared with controls (8.6%) (Odds ration (OR) = 2.21; 95% confidence interval (CI), 1.04-4.69; P = 0.0289). In addition, there was a statistically increased risk of prostate cancer among smokers with the NAT2 slow genotype (OR = 3.78: 95% CI, 1.48-9.66; P = 0.0041). Furthermore, the NAT2 slow acetylator genotype was significantly higher among prostate cancer patients with locally advanced and metastatic disease (22.7%) compared with controls (8.6%) (OR = 3.14; 95% CI, 1.40-7.06; P = 0.0051). Lastly, the NAT2 slow acetylator genotype was significantly higher among prostate cancer patients with high-grade tumors (31.4%) compared with controls (8.6%) (OR = 4.90; 95% CI, 1.97-12.20; P = 0.0010). CONCLUSION: These data demonstrate that the NAT2 slow acetylator genotype plays an important role in determining the risk of developing prostate cancer in Japanese men and is also associated with more clinically advanced and pathologically aggressive disease. Furthermore, a possible interaction between the NAT2 slow acetylator genotype and smoking status was suggested.
BACKGROUND: The purpose of this study was to determine the frequency of a polymorphism of the candidate metabolic enzyme N-acetyltransferase-2 (NAT2) in Japanese prostate cancerpatients and Japanese non-cancer controls, in order to determine if an association exists between NAT2 genotype and the occurrence, clinical stage and grade of prostate cancer. METHODS: In the present case-control study, 111 patients with prostate cancer and 152 controls were genotyped for the NAT2 polymorphism using the polymerase chain reaction-based restriction fragment length polymorphism method. The NAT2 genotypes (slow or rapid acetylator genotype) were determined by the combination of three known NAT2 mutant alleles (M1, M2, M3) and the wild-type allele. RESULTS: The NAT2 slow acetylator genotype was statistically higher among prostate cancerpatients (17.1%) compared with controls (8.6%) (Odds ration (OR) = 2.21; 95% confidence interval (CI), 1.04-4.69; P = 0.0289). In addition, there was a statistically increased risk of prostate cancer among smokers with the NAT2 slow genotype (OR = 3.78: 95% CI, 1.48-9.66; P = 0.0041). Furthermore, the NAT2 slow acetylator genotype was significantly higher among prostate cancerpatients with locally advanced and metastatic disease (22.7%) compared with controls (8.6%) (OR = 3.14; 95% CI, 1.40-7.06; P = 0.0051). Lastly, the NAT2 slow acetylator genotype was significantly higher among prostate cancerpatients with high-grade tumors (31.4%) compared with controls (8.6%) (OR = 4.90; 95% CI, 1.97-12.20; P = 0.0010). CONCLUSION: These data demonstrate that the NAT2 slow acetylator genotype plays an important role in determining the risk of developing prostate cancer in Japanese men and is also associated with more clinically advanced and pathologically aggressive disease. Furthermore, a possible interaction between the NAT2 slow acetylator genotype and smoking status was suggested.
Authors: Tristan M Sissung; John Deeken; Crystal R Leibrand; Douglas K Price; Sheryl Ehrlich; Seth M Steinberg; David J Liewehr; William Dahut; William D Figg Journal: Pharmacogenomics Date: 2016-11-24 Impact factor: 2.533
Authors: Marta Vilčková; Jana Jurečeková; Dušan Dobrota; Viera Habalová; Lucia Klimčáková; Iveta Waczulíková; Peter Slezák; Ján Kliment; Monika Kmeťová Sivoňová Journal: Med Oncol Date: 2014-05-11 Impact factor: 3.064
Authors: Mario Maciel de Lima Junior; Leonardo Oliveira Reis; Ana Carolina Trindade Guilhen; Fabiana Granja; Mariana Nicolau de Lima Oliveira; Ubirajara Ferreira; Lucas Leite Cunha; Laura Sterian Ward Journal: Med Oncol Date: 2012-01-14 Impact factor: 3.064
Authors: Emmanuel Y Jingwi; Muneer Abbas; Luisel Ricks-Santi; Danyelle Winchester; Desta Beyene; Agnes Day; Tammey J Naab; Olakunle O Kassim; Georgia M Dunston; Robert L Copeland; Yasmine M Kanaan Journal: Anticancer Res Date: 2015-03 Impact factor: 2.480
Authors: Sangita Sharma; Xia Cao; Lynne R Wilkens; Jennifer Yamamoto; Annette Lum-Jones; Brian E Henderson; Laurence N Kolonel; Loïc Le Marchand Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-06-22 Impact factor: 4.254
Authors: David F Barker; Anwar Husain; Jason R Neale; Benjamin D Martini; Xiaoyan Zhang; Mark A Doll; J Christopher States; David W Hein Journal: Pharmacogenet Genomics Date: 2006-07 Impact factor: 2.089